Showing results (1-10 of 19) with videos related to
Sort By:
Pageof 2
Thrombosis Research|June 18, 2014
Cost-effectiveness of apixaban versus warfarin and aspirin in Sweden for stroke prevention in patients with atrial fibrillationTereza Lanitis, Thitima Kongnakorn, Lena Jacobson, et al.Future Oncology (London, England)|November 6, 2019
Value assessment of immuno-oncology in the treatment of rare tumors in the era of accelerated conditional approvalsTereza Lanitis, Apoorva Ambavane, Ying Zheng, et al.Pharmacoeconomics|February 8, 2014
Assessing the value of healthcare interventions using multi-criteria decision analysis: a review of the literatureKevin Marsh, Tereza Lanitis, David Neasham, et al.Clinical Drug Investigation|August 29, 2014
Cost effectiveness of apixaban versus aspirin for stroke prevention in patients with non-valvular atrial fibrillation in BelgiumThitima Kongnakorn, Tereza Lanitis, Annemans Lieven, et al.Journal of Managed Care & Specialty Pharmacy|June 29, 2018
Intravitreal Aflibercept Versus Ranibizumab for Wet Age-Related Macular Degeneration: A Cost-Effectiveness AnalysisLuis Hernandez, Tereza Lanitis, Clifford Cele, et al.Stroke|August 29, 2015
Clinical and Economic Implications of Apixaban Versus Aspirin in the Low-Risk Nonvalvular Atrial Fibrillation PatientsGregory Y H Lip, Tereza Lanitis, Jack Mardekian, et al.Advances in Therapy|July 28, 2019
Survival Analysis in Patients with Metastatic Merkel Cell Carcinoma Treated with AvelumabTereza Lanitis, Irina Proskorovsky, Apoorva Ambavane, et al.Clinical Drug Investigation|December 17, 2014
Stroke and systemic embolism prevention in patients with atrial fibrillation in Belgium: comparative cost effectiveness of new oral anticoagulants and warfarinThitima Kongnakorn, Tereza Lanitis, Lieven Annemans, et al.BMC Health Services Research|January 25, 2017
Cost-effectiveness of apixaban versus low molecular weight heparin/vitamin k antagonist for the treatment of venous thromboembolism and the prevention of recurrencesTereza Lanitis, Robert Leipold, Melissa Hamilton, et al.Ophthalmic Surgery, Lasers & Imaging Retina|April 30, 2020
Social Cost of Blindness Due to AMD and Diabetic Retinopathy in the United States in 2020Andrew A Moshfeghi, Tereza Lanitis, Georg Kropat, et al.Pageof 2